FROM INNOVATIVE HOECHST RESEARCH

# **FPISIUM**<sup>®</sup> 10 mg (clobazam) ANTICONVULSANT FOR ADJUNCTIVE THERAPY

## EFFICACY

- Frisium is efficacious in all seizure types in both pediatric and adult patients.<sup>1</sup>
- Frisium achieves
  complete control in up to 30% of refractory
   patients depending on seizure type.<sup>1</sup>

## SAFETY

- Adverse events are generally mild and transient.<sup>2</sup>
- Clinically significant drug interactions are uncommon.
- Impairment of alertness is less pronounced with
   Frisium than with other benzodiazepines.\*

#### DOSAGE

 Daily doses up to 30 mg may be taken as a single dose at bedtime.

# IN EPILEPSY add Frisium<sup>®</sup> 10 mg (clobazam) TO ACHIEVE SEIZURE CONTROL

PAAB

Please consult precautions statement in product monograph.

, Hoechst and ®, Reg. Trademarks of Hoechst AG, Germany

Hoechst Canada Inc., Montreal H4R 1R6



# SCIENCE F

## There are ways of telling when a young epilepsy patient is on Tegretol<sup>®</sup> CR.

#### Excellent Seizure Control.

Tegretol CR (controlled-release carbamazepine) controls seizures in many patients-with little impact on cognitive function<sup>1,2,3,4</sup> Unlike drugs such as phenytoin, Tegretol CR can leave many patients free to think clearly and do their best.<sup>1,2,3,4</sup> **Consistent Blood Levels.** 

Tegretol CR delivers fewer "peaks and valleys" in blood levels than conventional Tegretol. That means fewer side effects and a more stable pattern of cognitive functioning<sup>5.6</sup>

#### Convenient B.I.D. Dosing.

When initiating or switching therapy, consider Tegretol CR. It comes in easy-to-break 200mg and



400mg tablets for dosage flexibility, and offers B.I.D. dosing to enhance patient compliance.



**Geigy** Mississauga, Ontario L5N 2W5 For brief prescribing information see pages xx, xxi , PAAB PMAC G-92111E